PDK1 and acute lymphoblastic leukemia: Alternatively, several PI3K inhibitors with distinct spectra of activity are in clinical development as combination therapies to eliminate drug-resistant ALL, such as the dual PI3K/mTOR inhibitor NVP-BEZ235 and the PI3K/PDK-1 inhibitor BAG956 [56], [57].